Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

EpiCept buying Maxim Pharma

September 12, 2005 | A version of this story appeared in Volume 83, Issue 37

EpiCept Corp. is acquiring Maxim Pharmaceuticals for $136 million in stock. The firm, which is keeping the EpiCept name, will focus on pain management and oncology drugs. EpiCept CEO Jack V. Talley will remain in place, as will the firm's New Jersey headquarters. EpiCept says it will continue to operate Maxim's research facility in San Diego. EpiCept shareholders will retain approximately 72% of the merged company's stock.

 

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.